Several CVD risk factors such as obesity, blood pressure and HDL cholesterol may be improved by SGLT2-i therapy, whereas the incidences of UTI and GTI are increased in the SGLT2-i groups. This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.